Company: BSD Medical Corp, BSDM
Price: 2.07
Change: +87.61%
Volume: 2.0M
BSD Medical Corp (BSDM) said it received U.S. regulatory approval to market its soft tissue ablation device, sending its shares up 42 percent in premarket trade, and up over 87% since market opening.
The company said the device, MicroThermX Microwave Ablation System (MTX-180), delivers targeted microwave energy to destroy soft tissue and is designed for the oncology market. Soft tissues connect, support or surround non-skeletal structures in the body, such as ligaments, tendons and fat.
BSD Medical said it expects a significant revenue stream from the device but did not disclose further details. The company estimates the soft tissue ablation world market potential to be over $2 billion.
BSD Medical Corporation develops, manufactures, markets, and services medical systems that deliver precision-focused radio frequency (RF) or microwave energy into diseased sites of the body, heating them to specified temperatures as required by a variety of medical therapies. The company develops technology and products for thermal ablation and hyperthermia cancer therapy through various techniques, which include thermal ablation that ablates soft tissues at high temperatures through focused microwave energy; superficial hyperthermia, which non-invasively treats cancerous tumors located within a few centimeters of the surface of the body
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
No comments :
Post a Comment